NCT04987671View on ClinicalTrials.gov

Pharmacokinetic and Pharmacodynamic Study of AMX0035 in Patients With ALS

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

August 5, 2021

Primary Completion Date

May 11, 2022

Study Completion Date

September 30, 2023

Conditions
ALS
Interventions
DRUG

AMX0035

Fixed dose combination of Sodium Phenylbutyrate and taurursodiol.

Trial Locations (1)

32608

Norman Fixel Institute for Neurological Diseases, Gainesville

Sponsors
All Listed Sponsors
lead

Amylyx Pharmaceuticals Inc.

INDUSTRY